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Abstract
Background: Treatment with radioactive iodine is effective for many patients with progressive, locally advanced or
metastatic, differentiated thyroid cancer. However, some patients become refractory to treatment. These types of
patients are considered to have radioactive iodine refractory differentiated thyroid cancer (RR-DTC).
Methods: We searched Embase, MEDLINE, PubMed and the Cochrane Library from January 1999 through January
2017. Reference lists of included studies and ongoing trial registries were also searched. Reports of randomized
controlled trials (RCTs), prospective observational studies, and systematic reviews/indirect comparisons were eligible
for inclusion. In the absence of direct clinical trial evidence comparing lenvatinib versus sorafenib, we assessed the
feasibility of conducting an indirect comparison to obtain estimates of the relative efficacy and safety of these two
treatments.
Results: Of 2364 citations, in total, 93 papers reporting on 2 RCTs (primary evidence), 9 observational studies and
13 evidence reviews (supporting evidence) were identified. Compared to placebo, RCT evidence demonstrated
improvements with lenvatinib or sorafenib in median progression-free survival (PFS) and objective tumour response
rate (ORR). Overall survival (OS) was confounded by high treatment crossover (≥75%) in both trials. Adverse events
(AEs) were more common with lenvatinib or sorafenib than with placebo but the most common AEs associated
with each drug differed. Primarily due to differences in the survival risk profiles of patients in the placebo arms of
the RCTs, we considered it inappropriate to indirectly compare the effectiveness of lenvatinib versus sorafenib. ORR
and AE findings for lenvatinib and sorafenib from the supporting evidence were broadly in line with RCT evidence.
Health-related quality of life (HRQoL) data were limited.
Conclusions: Lenvatinib and sorafenib are more efficacious than placebo (a proxy for best supportive care) for
treating RR-DTC. Uncertainty surrounds the extent of the impact on OS and HRQoL. Lenvatinib could not reliably be
compared with sorafenib. Choice of treatment is therefore likely to depend on an individual patient’s circumstances.
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Background
Thyroid cancer accounts for approximately 1% of all
new malignancies in the United Kingdom (UK) [1] and
approximately 3% of all new malignancies in the United
States (US) [2]. Commonly asymptomatic and so often
discovered incidentally [3], the most common type of
thyroid cancer is differentiated thyroid cancer (DTC). A
review of 2936 US patients registered with DTC found
papillary carcinoma (PTC), follicular carcinoma (FTC)
and Hürthle cell carcinoma to constitute 86, 10 and 4%
of cases respectively [4]. Globally, DTC incidence is in-
creasing [5]. In part, this increase has been attributed to
improved diagnostic and detection techniques [6].
Surgery followed by daily oral medication (levothyrox-
ine) to suppress blood thyroid stimulating hormone
(TSH) levels is the mainstay of treatment for DTC [7–10].
Additional treatment in the form of radioactive iodine
may be required for patients who develop local, regional
or metastatic disease (5 to 20% patients [7, 9]). For most
patients, radioactive iodine treatment is effective. How-
ever, 5 to 15% [4, 11–15] of people with DTC develop
radioactive iodine refractory differentiated thyroid cancer
(RR-DTC), i.e. they are unable to safely tolerate treatment
or they develop DTC that has become resistant to
treatment.
For patients with RR-DTC, treatment options have
been limited. Chemotherapy is rarely or never recom-
mended by the authors of clinical guidelines [7–10] and
thus, for many patients, best supportive care (BSC) has
been the only treatment option. However, the authors of
published clinical guidelines have noted the promise of
targeted therapies including tyrosine kinase inhibitors
(TKIs). Lenvatinib is the most recent TKI to be licensed
for treating RR-DTC, receiving a licence in the US in
February 2015 [16] and in the European Union (EU) in
May 2015 [17]. The only other licensed TKI is sorafenib,
which was licensed for the treatment of RR-DTC in the
US in November 2013 [18] and in the EU in January
2015 [19]. The authors of the US National Comprehen-
sive Cancer Network (NCCN) guidelines now recom-
mend that lenvatinib and sorafenib should be considered
for treating progressive and/or symptomatic RR-DTC
[10]. The authors, however, caution against their use for
patients with stable or slowly progressive indolent dis-
ease [10]. The authors of the American Thyroid Associ-
ation (ATA) guidelines caution that patients who are
candidates for TKI therapy “should be thoroughly coun-
seled on the potential risks and benefits of this therapy
as well as alternative therapeutic approaches including
best supportive care” [7]. Important risks associated with
lenvatinib highlighted by regulatory agencies [16, 17] in-
clude: hypertension; cardiac dysfunction; arterial
thromboembolic events; hepatotoxicity, renal failure or
impairment; proteinuria; diarrhea; fistula formation and
gastrointestinal perforation; QT interval prolongation;
hypocalcemia; reversible posterior leukoencephalopathy
syndrome; hemorrhagic events; impairment of TSH sup-
pression/thyroid dysfunction; wound healing complica-
tions; and embryo-fetal toxicity. Important risks
associated with sorafenib highlighted by regulatory agen-
cies [18, 19] include: dermatologic toxicities including
severe skin adverse events (AEs) and hand-foot syn-
drome; hypertension; posterior reversible encephalop-
athy syndrome; hemorrhage (including lung
hemorrhage, gastrointestinal hemorrhage and cerebral
hemorrhage); arterial thrombosis (myocardial infarction);
congestive heart failure; QT interval prolongation; squa-
mous cell cancer of the skin; gastrointestinal perforation;
symptomatic pancreatitis and increases in lipase and
amylase; hypophosphatemia; renal dysfunction; intersti-
tial lung disease-like events; drug-induced hepatitis; im-
pairment of TSH suppression; and embryo-fetal toxicity.
While lenvatinib and sorafenib are available for treat-
ing RR-DTC in several countries, the extent to which
they are available to patients has varied. For example,
lenvatinib and sorafenib are available for all patients
who require these treatments in Scotland via the
National Health Service (NHS) [20, 21]. However, prior
to August 2018, they were only available for patients in
special circumstances in the NHS in England. In order
to be routinely used in the NHS in England, a positive
recommendation from the National Institute for Health
and Care Excellence (NICE) is required. We, the Liver-
pool Reviews and Implementation Group (LRiG), were
commissioned, in our capacity as an independent
Assessment Group, to provide an independent review of
the clinical and cost effectiveness evidence as part of a
NICE multiple technology appraisal (MTA). In this
paper, we report our systematic review of the clinical
effectiveness evidence for lenvatinib and sorafenib and
discuss how the evidence has impacted on NICE recom-
mendations for clinical practice.
Methods
Our systematic review protocol was registered with
PROSPERO, the international prospective register of sys-
tematic reviews (registration number CRD42017055516).
The review was conducted in accordance with the
Centre for Reviews and Dissemination (CRD) published
guidance on conducting systematic reviews in healthcare
[22] and the review is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [23].
Search methods for identification of studies
On 10 January 2017, four electronic databases (Embase
(Ovid), MEDLINE (Ovid), PubMed and the Cochrane
Library) were searched for studies published since 1
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January 1999. On 16 May 2017, the clinicaltrials.gov
website (a service of the US National Institutes of
Health), the International Clinical Trials Registry Plat-
form and the European Union Clinical Trials Register,
were searched for information on studies in progress. To
identify relevant studies, a combination of index terms
for the disease (e.g. thyroid neoplasms) and free text
words (e.g. lenvatinib or Lenvima or E7080 or Sorafenib
or Nexavar or bay439006) were employed. The database
searches were limited to human research and English
language studies. No other search restrictions were ap-
plied. The search strategies employed are provided in
Additional file 1: Online Resource 1.
Evidence submissions from the sponsors of lenvatinib
[24] and sorafenib [25] that were submitted to NICE as
part of the MTA process were considered for inclusion
in our review. The lists of references from the company
submissions and all relevant studies identified via the lit-
erature searches were cross-checked to identify any pa-
pers not identified by the electronic searches.
Study selection and data extraction
Randomized controlled trials (RCTs), prospective obser-
vational studies and systematic reviews/indirect compar-
isons (hereafter referred to as evidence reviews) of
lenvatinib or sorafenib were selected for inclusion in the
review. To be included, the population must have in-
cluded adults with progressive, locally advanced or meta-
static thyroid cancer refractory to radioactive iodine, of
which at least a subgroup of patients had RR-DTC. A
summary of the a priori inclusion and exclusion criteria
are provided in Table 1.
Two reviewers independently screened all titles and
abstracts (screening stage 1). Full-text articles of all po-
tentially relevant citations identified during screening
stage 1 were retrieved and assessed for eligibility based
on the inclusion criteria (screening stage 2). Where
necessary, any discrepancies or uncertainties were re-
solved by discussion or consultation with a third
reviewer.
Two reviewers independently extracted and checked
data by using a pre-tested data extraction form. Data
were extracted relating to study design, patient charac-
teristics and outcomes for RCTs and observational stud-
ies and the number and type of studies included, type of
analysis conducted and the overall findings/conclusions
for evidence reviews. For all study types, data reported
in multiple publications were extracted and reported as
a single study.
Quality assessment
The quality of included RCTs and evidence reviews was
assessed according to the criteria set out in the Centre
for Review and Dissemination’s Guidance [22] for
undertaking reviews in healthcare. Two reviewers inde-
pendently assessed the quality of these studies and,
where necessary, disagreements were resolved by con-
sultation with a third reviewer. In accordance with the
protocol, quality assessment of the prospective observa-
tional studies was not conducted.
Data synthesis
Data from the included RCTs were considered to pro-
vide primary clinical effectiveness evidence. Data from
observational studies and from evidence reviews were
considered to provide supporting evidence.
Results
Literature search and screening
The process of study selection is shown in Fig. 1. The
electronic database searches yielded 2358 papers and six
additional references were identified through searches of
the other sources. In total, 93 papers reporting on 24
separate studies and reviews were identified. These
Table 1 Inclusion / exclusion criteria
Criteria Inclusion Exclusion
Patient population Adults with progressive, locally advanced or metastatic,
differentiated thyroid carcinoma, refractory to radioactive
iodine
Patients with other types of thyroid cancer or diseases
Interventions Lenvatinib or sorafenib monotherapy (or in combination
with best supportive care)
Lenvatinib or sorafenib in combination with other agents
Comparatorsa Lenvatinib or sorafenib monotherapy (or in combination
with best supportive care), best supportive care, placebo
A comparator other than lenvatinib, sorafenib, best
supportive care, placebo
Outcomes The outcome measures to be considered include: overall
survival, progression-free survival, response rate, adverse
effects of treatment, health-related quality of life
No study was excluded based on outcomes
Study design Randomized controlled trials, systematic reviews,b
prospective observational studies
Retrospective cohort studies, case series, case reports,
comments, letters, editorials, in vitro, animal, genetic or
histochemical studies
aWhere studies included a comparator arm
bAt the inclusion stage, published reports of indirect comparisons were also included if the indirect comparison was based on RCT evidence, even if the conduct
of a systematic review was not reported alongside the indirect comparison
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included two RCTs [the SELECT trial [26] and DECI-
SION trial [27]], nine prospective observational studies
[28–36] and 13 evidence reviews [24, 25, 37–47].
For the RCTs, in addition to the primary published pa-
pers [26, 27], data were extracted from other sources
identified from the searches, as appropriate. In this
paper, additional information for the SELECT trial was
extracted from the company submission from Eisai Ltd.
[24], the clinical study report (CSR) (unpublished), three
conference abstracts [48–50] and the European public
assessment report (EPAR) for lenvatinib [51]. For the
DECISION trial, additional information was extracted
from the company submission from Bayer HealthCare
[25], an additional published paper with supplementary
safety data [52], the CSR (unpublished), three conference
abstracts [53–55] and the EPAR for sorafenib [56].
For one of the included prospective observational
studies of sorafenib, known as UPCC-03305 [32], the
majority of data were extracted from later conference re-
ports of the same study [57–59] which reported baseline
characteristics from a greater number of patients [58],
efficacy data [59] and safety data [57].
Characteristics of included studies
Characteristics of randomized controlled trials (primary
evidence)
Both of the included RCTs [26, 27] were phase III multi-
centre double-blind trials designed to compare the inter-
vention of interest (lenvatinib or sorafenib) with placebo.
Subjects were randomized 2:1 to the intervention and
comparator arms of the SELECT trial (lenvatinib, n =
261; placebo, n = 131) [26] and 1:1 in the DECISION
Fig. 1 PRISMA flow diagram: studies included in systematic review
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trial (sorafenib, n = 207; placebo, n = 210) [27]. Both tri-
als permitted some concomitant therapies (such as TSH
suppression) in both the intervention and placebo arms.
Thus, the placebo arm in both trials could be considered
to be equivalent to BSC. The types of concomitant ther-
apies were broadly similar in both trials. However, a po-
tentially important difference between the two trials was
that palliative radiotherapy, which is commonly available
as part of BSC in clinical practice, was only permitted in
the DECISION trial, not the SELECT trial. Nonetheless,
rates of palliative radiotherapy administered to patients
in the DECISION trial were relatively low: 10.6% of pa-
tients treated with sorafenib and 21.4% of patients
treated with placebo [25].
Patients were eligible to receive treatment (interven-
tion or placebo) in both the SELECT and DECISION
trials until disease progression [26, 27]. In both trials,
patients were then enrolled into open extension
phases [24, 25]. In the DECISION trial, patients who
had progressed on sorafenib were permitted to con-
tinue to receive sorafenib until further disease
progression and approximately a quarter (26.6%) of
patients did so [53, 54]. In both the SELECT and DE-
CISION trials, patients in the placebo arms could
cross over from the placebo arm to the active treat-
ment arm. Patient crossover on disease progression
was high in both trials (SELECT: 87.8%, DECISION:
75%) [24, 25]. In addition, in both trials, patients in
either arm were also eligible to receive subsequent
anti-cancer treatments that were not part of the trial
protocols [24, 25]. In the SELECT trial, at the pri-
mary data-cut, 15.7% of patients randomized to lenva-
tinib and 12.2% of patients randomized to placebo,
had received subsequent treatment (data from CSR)
including treatment with another TKI (data from
CSR). Of those who received subsequent treatment,
17.1% of patients in the lenvatinib arm received pazo-
panib and 14.6% received sorafenib (data from CSR).
In the placebo arm, the respective proportions were
18.8 and 12.5% (data from CSR). In the DECISION
trial, at the primary data-cut, 20.3% of patients ran-
domized to sorafenib and 8.6% of patients randomized
to placebo received subsequent treatments [27]. Infor-
mation on the specific agents used during the DECI-
SION trial follow-up period was not collected.
The median duration of follow-up at the primary data-
cut was approximately 17 months in both trials [26, 27].
OS results were also reported at a second and third
data-cut in both trials [24, 25]. At the third data-cut, the
median length of follow-up was approximately 38
months in the SELECT trial [24] and 36months in the
sorafenib arm of the DECISION trial [25] (length of
follow-up data have only been reported for the sorafenib
arm of this trial).
The OS results from both trials were adjusted for
treatment crossover using the Rank Preserving Struc-
tural Failure Time Model (RPSFTM) [60]. No adjust-
ments were made, in either trial, to take into account
subsequent anti-cancer treatment, as there is no recog-
nised approach for making such adjustments.
A key difference in eligibility between the two RCTs
was that the SELECT trial permitted the enrolment of
patients who had been previously treated with a TKI (in-
cluding sorafenib) [26], whilst patients recruited to the
DECISION trial were all TKI naïve [27]. Overall, 25.3%
of patients in the lenvatinib arm and 20.6% of patients in
the placebo arm of the SELECT trial had received prior
treatment with a TKI [26]. Approximately three quarters
of patients who received a TKI in the SELECT trial had
previously been treated with sorafenib (77.2% in the len-
vatinib arm and 77.8% in the placebo arm) [26].
Characteristics of prospective observational studies and
evidence reviews (supporting evidence)
All nine of the prospective observational studies were
single arm studies and included patients whose disease
was described as being radioactive iodine refractory
[28–30, 33, 35, 36], resistant to radioactive iodine [31,
32] or who may have received multiple treatments of
radioactive iodine [34]. Two studies [29, 36] investigated
the efficacy and safety of lenvatinib and seven studies con-
sidered the efficacy of sorafenib [28, 30–35]; one study in-
cluded no safety data [34].
Most of the observational studies were conducted in
single countries (and often in single centres) in Europe
[28, 31, 34, 35], the US [33, 58], and Asia [30, 36]. How-
ever, there was one multi-centre international study of
lenvatinib (Study 201) [29]. Where reported, patients
were recruited prior to the commencement of the SE-
LECT [26] and DECISION [27] trials, the exception was
a Japanese study of lenvatinib (Study 208) [36] that
began after recruitment to the SELECT trial had ended.
The median length of follow-up, as reported in the
EPAR for lenvatinib [56], was longer in the observational
studies of lenvatinib [29, 36] than in the SELECT trial
[24]: 40 months in Study 208 [56] and 51.6 months in
Study 201 [56]. Conversely, where reported [28, 34, 35],
the median length of follow-up in the observational
studies of sorafenib was shorter for OS but longer for
other outcomes than in the DECISION trial [25]: 19
months [34] to 25 months [35].
The number of patients included in the nine prospect-
ive observational studies varied from nine [30] to 58
[29]. In total, across all studies, 109 patients were treated
with lenvatinib, of whom 83 had RR-DTC; 213 patients
were treated with sorafenib, of whom 186 had RR-DTC.
Other patients included in four of the studies [28, 33,
36, 58] had anaplastic (n = 26) or medullary (n = 27)
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carcinoma. Participant characteristics were reported for all
treated patients in each study and, where reported, median
age ranged from 55 years [28] to 64 years [33]. Where re-
ported, four studies included a majority of males [28, 29,
33, 35] and three studies included a majority of females
[31, 34, 58]. Only two studies explicitly stated that patients
could have received a prior TKI [29, 34] and, in these
studies, the proportion of patients who did receive a prior
TKI ranged from 11.8% [34] to 29.3% [29].
Overall, 11 evidence reviews included evidence for
lenvatinib and sorafenib [24, 25, 37–43, 46, 47]. Two
reviews only included observational studies of sorafe-
nib [44, 45].
The earliest review, which presented evidence narra-
tively, was published in 2013 [37] and the most recent
reviews (from 2017) were the evidence submissions from
the sponsors of lenvatinib [24] and sorafenib [25]. Both
of the evidence submissions [24, 25] included modified
versions of the indirect comparisons of lenvatinib versus
sorafenib originally conducted by Tremblay et al. 2016
[46]; the original results [46] were also reported in the
Canadian Agency for Drugs and Technologies in Health
(CADTH) submission for lenvatinib [39]. One other
publication [42], included an indirect comparison of len-
vatinib versus sorafenib. The two reviews that included
only observational studies of sorafenib meta-analyzed
the data from the studies they included [44, 45].
Quality assessment of included studies
Overall, the risk of bias was considered to be low in both
RCTs (Additional file 2: Online Resource 2). The quality
of nine of the evidence reviews [24, 25, 37–39, 42–45]
was considered to be good (Additional file 3: Online
Resource 3).
Results from the included studies
Primary evidence efficacy evidence
We have reported RCT evidence from the primary data-
cuts of the SELECT and DECISION trials [26, 27], with
the exception of OS data, which are reported for the
third data-cut [24, 25]. The results for OS, PFS and ORR
from the RCTs are summarized in Table 2.
For OS, no statistically significant differences between
trial arms were found in either trial [24, 25]. When OS
results from both trials were adjusted for treatment
crossover, the difference was reported to be statistically
significant in the SELECT trial, favouring lenvatinib over
placebo [24] but a similar finding was not reported in
the DECISION trial for sorafenib versus placebo [25].
Compared to placebo, median PFS and ORR were im-
proved with lenvatinib in the SELECT trial [26] and with
sorafenib in the DECISION trial [27]. The difference in
ORR between trial arms was particularly pronounced in
the SELECT trial, difference in ORR 63.2% (95% CI: 57.1
to 69.4%) [26]; the difference in ORR in the DECISION
trial was 11.7% (95% CI: 7.0 to 16.5%). Differences be-
tween arms were reported to be statistically significant
for PFS and ORR in both trials [26, 27].
As some patients in the SELECT trial had previously
received a TKI (including sorafenib), subgroup analyses
were conducted to assess the effect of this previous
treatment and the results have been reported for median
PFS and ORR [26]. Median PFS was longer for patients
treated with lenvatinib compared with placebo, irre-
spective of whether patients had received a TKI [26].
Median PFS for those previously treated was 15.1 versus
3.1 months (HR 0.22, 95% % confidence interval [CI]:
0.12 to 0.41) and for TKI-naïve patients median PFS was
18.7 versus 3.6 months (HR 0.20, 95%CI CI: 0.14 to 0.27)
[26]. Similarly, ORR was improved for patients treated
with lenvatinib whether or not they had been previously
treated with a TKI (62.1% versus 3.7%; odds ratio [OR]
15.57, 95% CI: 4.06 to 59.72), or not (65.6% versus 1.0%;
OR 58.88, 95% CI: 18.95 to 182.91) [26].
Table 2 Summary of efficacy findings from the SELECT and
DECISION trials










Median, months 41.6 34.5 39.4 42.8
(95% CI) (31.2-NE) (21.7-NE) (32.7–51.4) (34.7–52.6)
Unadjusted HR (95% CI) 0.84 (0.62–1.13) 0.92 (0.71–1.21)
RPSFTM adjusted OS HR 0.54 0.77
(95% CI) b (0.36–0.80) (0.42–1.79)
PFSc
Median, months 18.3 3.6 10.8 5.8
(95% CI) (15.1-NE) (2.2–3.7) (CIs NR) (CIs NR)
Stratified HR (95% CI) 0.21 (0.14–0.31) 0.59 (0.45–0.76)
Objective tumour response
ratec, d (%) 64.8 1.5 12.2 0.5
(95% CI) (59–70.5) (0–3.6) (8–17.7) (0–2.7)
Odds Ratio (95% CI) 28.87 (12.46–66.86) NR
P value p < 0.0001 p < 0.0001
CI Confidence interval, HR Hazard ratio, IPE Iterative Parameter Estimation, NE
Not estimable, NR Not reported, OS Overall survival, PFS Progression-free
survival, RPSFTM Rank Preserving Structural Failure Time Model
aData from final data-cut
bBootstrapping CIs
cAssessed by blinded independent review at primary data-cut
dUnlike the SELECT trial, patients who were unevaluable for response were
excluded from the analyses in the DECISION trial. There were 18 (4.3%)
patients who were excluded from the objective tumour response analyses in
the DECISION trial, 9 (4.3%) patients in each arm [27]
Source: [26, 27] with additional OS data from Eisai Ltd. 2017 [24] and Bayer
HealthCare 2017 [25] and additional ORR data (95% CIs) from European public
assessment report (EPAR) for lenvatinib [51] and EPAR for sorafenib [56]
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Indirect comparison of lenvatinib versus sorafenib
In the absence of direct clinical trial evidence comparing
treatment with lenvatinib versus treatment with sorafe-
nib, we assessed the feasibility of conducting an indirect
comparison to obtain estimates of the relative efficacy
and safety of these two treatments. As both the SELECT
and DECISION trials shared a common comparator
(placebo), it is possible to construct a network. Indeed,
indirect comparisons have been reported in evidence re-
views [24, 25, 39, 42, 46]. For an indirect comparison to
be reliable: (i) trial and participant characteristics must
be sufficiently similar (ii) survival hazard profiles for the
shared comparator should be similar and (iii) within tri-
als, hazards should be proportional (since Cox propor-
tional hazard [PH] modelling [61] was used to generate
OS, RPSFTM-adjusted OS and PFS hazard ratios [HRs]).
We therefore tested whether all these assumptions were
supported by the data.
In relation to (i), we found that there were a number
of differences in trial and participant characteristics,
which were most pronounced when comparing the pla-
cebo arms of the two trials, as highlighted in Table 3. In
relation to (ii), from an examination of PFS data, it was
also evident that the survival risk profiles of the shared
comparator (the placebo arms) were not comparable
(Fig. 2). In relation to (iii), we tested the validity of the
proportional hazards assumption for OS, RPSFTM-
adjusted OS and PFS against a non-linear (quadratic)
counterfactual using an analysis of variance (ANOVA)
test. With the exception of unadjusted OS data in the
DECISION trial, we found the PH assumption was vio-
lated and thus the network of evidence was compro-
mised for all efficacy outcomes. Therefore, we did not
undertake an indirect comparison to compare the effi-
cacy of lenvatinib versus sorafenib.
Supporting efficacy evidence
Efficacy findings from the observational studies [28–31,
33–36, 59], and meta-analyses conducted by the authors
of two sorafenib reviews [44, 45] are summarised in
Table 4. Data were also extracted from the EPAR for so-
rafenib [56] for OS and ORR for one of the observational
studies [33] and for ORR for another observational study
[28]. This is because these results were not presented
only for patients with RR-DTC in the published papers
of these studies.
Median OS reported in both observational studies of
lenvatinib [29, 36] was approximately 32 months, lower
than the median OS estimates reported for both arms of
the SELECT trial (lenvatinib: 41.6 months, placebo: 34.5
months) [24]. Similarly, median OS reported in three
studies of sorafenib [33, 35, 59], which ranged from 23
months [33] to 34.5 months [35], was lower than median
OS reported in either arm of the DECISION trial
(sorafenib: 39.4 months, placebo: 42.8 months) [25]. Me-
dian OS could not be estimated in one other study of so-
rafenib, as it had not yet been reached [28].
Median PFS and ORR for patients treated with lenvati-
nib were lower in one study (median PFS: 12.6 months,
ORR: 50%) [29] and higher in another (median PFS:
25.8 months, ORR: 68%) [36] than reported for patients
treated with lenvatinib in the SELECT trial (median PFS:
18.3 months, ORR: 64.8%) [26]. Median PFS was higher
in all four prospective observational studies that re-
ported a median [33–35] as was ORR in all prospective
observational studies [28, 30, 31, 33–35, 59] than in the
DECISION trial [27]; range of median PFS was 12
months [34] to 22.1 months [59] in the observational
studies and 10.8 months in the sorafenib arm of the DE-
CISION trial [27], range of ORRs was 15% [33] to 38.3%
[59] in the observational studies and 12.2% in the sorafe-
nib arm of the DECISION trial [27]. Reflecting these
findings, authors of the sorafenib meta-analyses of
single-arm studies [44, 45] reported a higher median
PFS and ORR than reported for patients treated with so-
rafenib in the DECISION trial [27]; median PFS of 17.9
months [45] and ORR of 21 to 22% [44, 45] in the meta-
analyses.
Two published papers have reported efficacy results
from indirect comparisons of lenvatinib with sorafenib
[42, 46] utilising data from the SELECT and DECISION
trials [26, 27]. There were no statistically significant dif-
ferences in OS (whether RPSFTM-adjusted, or not) but
in both papers, it was reported that PFS was significantly
better with lenvatinib versus sorafenib (HR 0.36, 95% CI:
0.22 to 0.57) [42, 46]. The results from a matched ad-
justed indirect comparison (MAIC) for OS and PFS were
very similar to the unmatched results [46]. One of the
published papers also included a comparison for ORR
and found no statistical significance between lenvatinib
and sorafenib (relative benefit 1.72, 95% CI: 0.15 to
19.40) [42].
Primary safety evidence
Safety evidence from the SELECT and DECISION tri-
als is summarised in Table 5. The majority of AE
data for the SELECT trial is taken from the Eisai Ltd.
evidence submission [24] as, similar to the reporting
in the DECISION trial [27], this reported treatment-
emergent AEs, whereas the primary published paper
mostly reported treatment-related AEs [26]. Treat-
ment with both lenvatinib and sorafenib led to an in-
crease in the incidence of AEs versus treatment with
placebo [24, 27]. Dose interruptions and reductions
were very frequent for patients treated with both len-
vatinib and sorafenib [26, 27]. Fatal AEs were re-
corded for 7.7% of patients treated with lenvatinib
and 4.6% of patients who received placebo in the
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Table 3 Differences in characteristics of the SELECT and DECISION trials (bold text/shaded cells)
DTC Differentiated thyroid cancer, ECOG Eastern Cooperative Oncology Group, n/a Not applicable, NR Not reported, PS Performance status, TKI Tyrosine
kinase inhibitor
Sources: Eisai Ltd. 2017 [24, 26], EPAR for lenvatinib [27, 51] and appendix to Bayer HealthCare 2017 [25]
Text in bold relates to the most notable differences between placebo arms and shaded cells the most notable differences between trials in any arm
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SELECT trial [26]. Fatal AEs in the DECISION trial
were recorded for 5.8% of patients treated with soraf-
enib and 2.9% of patients in the placebo arm [27].
The most frequently reported AEs occurring in
around two-thirds of patients were, for lenvatinib,
hypertension and diarrhoea [24] and, for sorafenib,
hand-foot syndrome, diarrhoea and alopecia [27].
Hypertension was a very frequent Grade ≥ 3 AE
reported with lenvatinib [24] and hand-foot syndrome
was a frequent Grade ≥ 3 AE reported with sorafenib
[27].
Analyses have been undertaken to determine the me-
dian time to onset of five AEs for patients treated with
lenvatinib in the SELECT trial [48], and eight AEs with
for patients treated with sorafenib in the DECISION trial
[52]. The results suggest that, when treated with either
Fig. 2 Comparison of progression-free survival in the placebo arms of the DECISION and SELECT clinical trials. Source: Data provided during the
NICE appraisal by Eisai Ltd. and Bayer HealthCare








Estimate from meta-analysis by
Thomas et al. 2014 [45]
Estimate from meta-analysis
by Shen et al. 2014 [44]
OS, median 31.8–32.3 [2] 23–34.5 [3] a - c - c
PFS, median 12.6–25.8 [2] 12–22.1 [4] b 17.9 - c
95% CI 17.9–18 [7]
ORR, % 50–68 [2] 15–38.3 [7] 20.9 22
95% CI 14.3–27.5 [6] 15–28 [7]
- = not applicable, CI Confidence interval, ORR Objective tumour response rate, OS Overall survival, PFS Progression-free survival
aAn additional study reported that the median OS had not been met [28]
bOne other study reported that the median PFS had not been met [28] and another reported mean PFS only (9.7 months) [30]; in this latter study sorafenib was
studied at half the dose of all other studies and included only 9 patients
c No meta-analyses were identified
[x] denotes the number of studies from which data are derived
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lenvatinib or sorafenib, most AEs typically occur early,
with a decrease in incidence, prevalence and severity
over time [48, 52]. However, hypertension was a notable
AE omitted from the analysis of lenvatinib data [48].
The incidences of any all-Grade and Grade ≥ 3 AEs for
patients treated with lenvatinib were similar in patients
who had received a prior TKI to those who had not [49,
50]. The proportion of patients who had at least one len-
vatinib dose reduction was also similar between these
two subgroups [49, 50].
Supporting safety evidence
The safety data from the prospective observational stud-
ies of lenvatinib [29, 36], prospective observational stud-
ies of sorafenib [28, 33, 35, 57] and meta-analyses of
observational studies of sorafenib [44, 45] are sum-
marised in Table 6. Prospective observational study au-
thors report either treatment-emergent [28, 29, 35, 36]
or treatment-related AEs [33, 57]. The meta-analyses ap-
pear to include a combination of treatment-emergent
and treatment-related AEs [44, 45].
Although there were differences in the incidences of
some AEs across studies [28, 29, 33, 35, 36, 44, 45, 57]
and compared to the SELECT and DECISION trials [24,
27], the most common types of AEs with both drugs
were similar to those found in the RCTs. As with the
RCT evidence [26, 27], dose interruptions and reduc-
tions were very frequent for patients treated with either
lenvatinib [29] or sorafenib [35, 57].
One of the published reviews [42] compared the rela-
tive risk of AEs from treatment with lenvatinib with
treatment from sorafenib via an indirect comparison uti-
lising data from the SELECT and DECISION trials [26,
27]. The authors reported that the risk of all-Grade AEs
was similar (OR 2.55, 95% CI: 0.59 to 11.57) [42]. The
authors also tested for differences for 17 different types
of AEs (treatment-related for lenvatinib and treatment
emergent for sorafenib) and found that compared with
sorafenib, lenvatinib significantly increased the risk of
hypertension (risk ratio [RR] 2.31, 95% CI: 1.18 to 4.53)
but significantly reduced the risk of alopecia (RR 0.33,
95% CI: 0.12 to 0.94) [42]. There were no significant dif-
ferences for the other 15 AEs, which included the other
Table 5 Summary of safety data in the SELECT and DECISION trials









Any adverse event 260 (99.6) 118 (90.1) 204 (98.6) 183 (87.6)
Any Grade≥ 3 adverse event 223 (85.4) 39 (29.8) 133 (64.3) 63 (30.1)
Most common all-Grade AEsa
Hypertension 181 (69.3) 19 (14.5) 84 (40.6) 26 (12.4)
Diarrhoea 173 (66.3) 22 (16.8) 142 (68.6) 32 (15.3)
Decreased appetite / anorexia 139 (53.3) 24 (18.3) 66 (31.9) 10 (4.8)
Weight loss 132 (50.6) 19 (14.5) 97 (46.9) 29 (13.9)
Nausea 121 (46.4) 33 (25.2) 43 (20.8) 24 (11.5)
Fatigue 110 (42.1) 32 (24.4) 103 (49.8) 53 (25.4)
Hand-foot syndrome 84 (32.2) 1 (0.8) 158 (76.3) 20 (9.6)
Rash or desquamation 48 (18.4) 2 (1.5) 104 (50.2) 24 (11.5)
Alopecia 32 (12.3) 7 (5.3) 139 (67.1) 16 (7.7)
Most common Grade≥ 3 AEsb
Hypertension 112 (42.9) 5 (3.8) 20 (9.7) 5 (2.4)
Hand-foot syndrome 9 (3.4) 0 42 (20.3) 0
Weight loss 31 (11.9) 1 (0.8) 12 (5.8) 2 (1)
Proteinuria 26 (10) 0 0 0
Treatment interruptions, reductions or discontinuations because of an adverse event
Dose interruptions 215 (82.4) 24 (18.3) 137 (66.2) 54 (25.8)
Dose reductions 177 (67.8) 6 (4.6) 133 (64.3) 19 (9.1)
Discontinued treatment 43 (16.5) 6 (4.6) 39 (18.8) 8 (3.8)
a ≥ 40% in any arm
b ≥ 10% in any arm
Source: Eisai Ltd. 2017 [24, 26, 27] and clinical study report for the DECISION trial (unpublished)
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Median (95% CI) from
meta-analysis by
Thomas et al. 2014a
Median (95% CI) from
meta-analysis by
Shen et al. 2014
Most common all-Grade AEs (%)b
Hypertension 76–90 [2] 21–42 [3] 43 [2] 36 (27–46)[7] 52 (33–72)[7]
Diarrhoea 55–67 [2] 52–77 [3] 75–80 [2] 70 (62–78)[7] 68 (59–77)[7]
Decreased appetite 52–78 [2] 29 [1] 20–82 [2] – –
Weight loss 69 [1] 29–58 [2] 60–82 [2] 57 (39–75)[7] 52 (33–72)[7]
Nausea 50 [1] 10–27 [2] 30–55 [2] – –
Fatigue 60–73 [2] 59 [1] 63–66 [2] – –
Hand foot syndrome 22–77 [2] 71–79 [3] 63–91 [2] 74 (64–83)[7] 80 (68–91)[7]
Rash 24 [1] 55–88 [2] 79–85 [2] 67 (52–82)[7] 66 (50–82)[7]
Alopecia 9 [1] 52–74 [2] 43–79 [2] – –
Proteinuria 61–64 [2] – – – –
Stomatitis/ mucositis 31–57 [2] 27–48 [3] 16–47 [2] – –
Cough 45 [1] – – – –
Headache 43 [1] 15 [1] 16 [1] – –
Dysphonia 43 [1] – – – –
Infection – 68 [1] – – –
Hypocalcaemia – 48 [1] – – –
Dry skin – – 84 [1] – –
Pruritis – – 77 [1] – –
Flatulence – – 70 [1] – –
Abdominal/ rectal pain – – 68 [1] – –
Arthralgia – – 61 [1] – –
Most common Grade≥ 3 AEs (%)c
Hypertension 10 [1] 6–16 [2] 4–13 [2] 7 (3–12)[7] –
Hand foot syndrome 2 [1] 23–44 [2] 7 [2] 19 (8–31)[7] –
Weight loss 12 [1] 0–10 [2] 5–10 [2] 5 (1.2–9)[7] –
Proteinuria 10 [1] – – – –
Diarrhoea 10 [1] 3–7 [2] 4–7 [2] 7 (3–10)[7] –
Fatigue 9 [1] 9 [2] 16 [1] 10 (4–16)[7] –
Stomatitis/ mucositis 2 [1] 9–10 [2] 0–2 4 (1–7)[7] –
Rash 0 [1] 6–16 [2] 4–18 [2] 7 (3–11)[7] –
Myocardial infarction – 10 [1] – – –
Hand or foot pain – – 12 [1] – –
Arthralgia – – 11 [1] – –
Treatment interruptions, reductions or discontinuations because of an adverse event (%)
Dose interruptions 74 [1] 82 [1] – – –
Dose reductions 66 [1] 42–100 [2] 47–55 [2] – –
Discontinued treatment 2–26 [2] 23 [1] 20 [1] – –
- = not reported or not applicable; AE Adverse event, C Confidence interval, TEAE treatment-emergent adverse event; TRAE Treatment-related adverse event
aOne of the included studies did not include only patients with RR-DTC
b ≥ 40% in any study
c ≥ 10% in any study
[x] denotes the number of studies from which data are derived
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most common AEs reported in the SELECT and DECI-
SION trials [26, 27].
The authors of one of the indirect comparisons also pre-
sented results for serious AEs (SAEs), serious treatment-
related AEs and treatment discontinuation due to AEs
[42]. The only significant difference was that lenvatinib in-
creased the risk of serious treatment-related AEs com-
pared to sorafenib (RR 4.02, 95% CI: 1.69 to 9.6) [42].
Evidence for health-related quality of life with treatment
HRQoL data were only collected during the DECISION
trial and the results were presented in a conference
abstract [55] and in Bayer HealthCare’s evidence submis-
sion to NICE [25]. Cancer-specific HRQoL was mea-
sured using the Functional Assessment of Cancer
Therapy - General (FACT-G) questionnaire [62] and
general health status was measured using the generic
EuroQol five dimensions, three-level questionnaire (EQ-
5D-3 L) and the EQ-5D visual analogue scale (VAS) [63].
All questionnaires were self-administered at baseline and
day 1 of every 28-day cycle until disease progression
[55]. The overall questionnaire completion rate during
the DECISION trial was reported to be > 96% [25].
At baseline, patients’ HRQoL data were considered by
the authors to be comparable to a normative adult can-
cer population [25, 55]. However, at the first assessment
(cycle 2, day 1), HRQoL scores (FACT-G, EQ-5D-3 L
and VAS) had deteriorated in the sorafenib arm [25, 55].
Thereafter, the sorafenib arm scores remained similar to
the scores recorded at the first assessment until disease
progression [25, 55]. Scores for the placebo arm
remained very similar to the baseline scores at the
first assessment and all subsequent assessments until
disease progression [25, 55]. Results from a mixed lin-
ear model showed that, compared with placebo, the
FACT-G score was 3.45 points lower in the sorafenib
arm than the placebo arm (p = 0.0006) [25, 55]. This
is reported to represent a clinically meaningful differ-
ence between arms in favour of the placebo arm [25,
55]. While the between arm differences were sta-
tistically significant for both EQ-5D-3 L and VAS
(p < 0.0001), the treatment effects (− 0.07 and − 6.75,
respectively) were reported to be of a small magni-
tude which did not reach the threshold considered to
represent a clinically meaningful difference [25, 55].
Discussion
The aim of this review was to compare the clinical
effectiveness evidence for lenvatinib or sorafenib in rela-
tion to BSC and also to compare the effectiveness of
both drugs with each other.
Trial results show that both drugs are more efficacious
in terms of median PFS [26, 27] and ORR [26, 27] but
also result in more AEs than placebo [24, 27]. Placebo
can be considered to be a proxy for BSC in both trials,
even though concurrent use of palliative radiotherapy
was not permitted for patients in the SELECT trial (data
from CSR). Some of the most common types of AEs dif-
fer by drug, most notably hypertension being very com-
mon with lenvatinib [24] and hand-foot syndrome being
very common with sorafenib [27]. We were unable to
determine the true impact of lenvatinib and sorafenib on
OS or how both drugs, particularly lenvatinib, impact
upon HRQoL. This is because OS is confounded by
treatment crossover in both trials [26, 27] and HRQoL
data is limited to reports of sorafenib from the DECI-
SION trial [25, 55].
It should however be noted that results for OS (except
in the case of the DECISION trial), RPSFTM-adjusted
OS and PFS described as statistically significant (or
otherwise) should be interpreted with caution, since we
found for that for these outcomes, the PH assumption
was violated. It is therefore not possible to ascertain
whether the HRs are overestimates or underestimates of
the effect of the intervention versus placebo in either
trial.
In conducting a feasibility assessment of performing
indirect comparisons, we identified potential differences
in trial and population characteristics at baseline. Since
the PH assumption for OS and PFS data were also found
to be violated, we considered that the validity of con-
ducting an indirect comparison (matched or otherwise)
using standard methods was questionable. Importantly,
we also identified differences in the survival risk profiles
of patients in the placebo arms of the trials. These differ-
ences may reflect known or unknown differences in trial
and participant characteristics. The identification of
these differences was our primary reason for considering
an indirect comparison to be inappropriate. Of note, the
CADTH have also considered the populations to be dif-
ferent, stating that the SELECT trial population had
more aggressive disease as reflected by PFS in the pla-
cebo arms [39]. Furthermore, in its consideration of the
evidence base during the MTA process, the NICE Ap-
praisal Committee agreed that the Kaplan-Meier plots
for PFS in the placebo arms of the trials were sufficiently
different to suggest there were important differences
limiting the robustness of the indirect comparisons [64].
NICE guidance is based on the recommendations of
the NICE Appraisal Committee. The extent to which the
findings from either of the SELECT and DECISION
trials are generalizable to clinical practice was one of the
key considerations for the NICE Appraisal Committee
[64]. In clinical practice, patients are often not treated
with lenvatinib or sorafenib unless their disease is symp-
tomatic, or they have clinically significant progressive
disease (e.g. obvious radiological or biochemical progres-
sion). Data published in the EPAR for sorafenib [56]
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indicate that approximately 20% of patients in the DECI-
SION trial had been retrospectively defined as being
symptomatic; the equivalent proportion in the SELECT
trial was unknown. To be eligible for entry into both tri-
als, patients were required to have had radiographic evi-
dence of disease progression within the last 12 months
(SELECT trial) or 14 months (DECISION trial) [26, 27].
Arguably these eligibility criteria suggest that patients
had clinically significant disease that was likely to be rap-
idly progressing, if left untreated. Indeed, clinical opinion
presented to the NICE Appraisal Committee was that if
patients were not yet symptomatic in the trials, it was
likely they would soon become symptomatic [64]. The
evidence from both trials, even though it appears to in-
clude slightly different trial populations, was, therefore,
considered to be generalizable to clinical practice.
In the absence of results from reliable indirect com-
parisons, findings from observational studies provide im-
portant supporting evidence. The magnitude of effects in
relation to OS, PFS and the incidence of some AEs dif-
fered in prospective observational studies [28–31, 33–36,
57, 59] and meta-analyses [44, 45] to the RCT findings
[24–27]. There are a number of reasons that could
explain this. First, as with the RCTs, differences in un-
known patient characteristics may be contributory fac-
tors. Second, the differing lengths of follow-up should be
considered. Third, all of the prospective observational
studies were relatively small, and so the results are more
prone to being influenced by any outlying cases. How-
ever, while caution needs to be exercised in comparing
results across studies of different study populations, the
combined evidence from RCTs [26, 27] and observa-
tional studies [28–31, 33–36, 59] suggests ORR may be
higher for patients treated with lenvatinib than for
patients treated with sorafenib. Evidence from observa-
tional studies [28–31, 33, 35, 36, 57] and meta-analyses
[44, 45] also show that many common AEs reported
with lenvatinib and sorafenib in the RCTs [26, 27] are
also experienced by patients treated with these drugs in
other study populations. The evidence shows that some
AEs are very common to both lenvatinib and sorafenib
(e.g. diarrhoea), whereas other AEs tend to be more drug
specific (e.g. hypertension with lenvatinib and hand-foot
syndrome with sorafenib) [28, 29, 33, 35, 36, 44, 45, 57].
Therefore, the body of evidence taken as a whole sup-
ports the NCCN recommendation that “The decision of
whether to use lenvatinib (preferred) or sorafenib should
be individualized for each patient based on likelihood of
response and comorbidities” [10].
No HRQoL data for lenvatinib are available from
either the SELECT trial or the supporting observational
studies, [29, 36]. Only the DECISION trial collected
HRQoL data for patients treated with sorafenib, and
then only until the end of treatment [25, 55]. In the
DECISION trial, “mild” reductions in HRQoL were re-
ported for patients treated with sorafenib compared to
those receiving the placebo [25, 55]. Given the different
objective tumour response rates and types of AEs re-
ported in the studies of lenvatinib, HRQoL data for pa-
tients treated with lenvatinib would have been very
informative. It is unclear whether, for patients treated
with lenvatinib, obtaining an objective response to treat-
ment is associated with improved HRQoL, or if they too
would experience “mild” reductions in HRQoL. The ex-
ploration of HRQoL associated with treatment with both
drugs is an area requiring further research.
Another area where further research is required relates
to the sequential use of lenvatinib and sorafenib. Sub-
group analysis results from the SELECT trial suggest
that differences in PFS, ORR and AEs for lenvatinib ver-
sus placebo were similar regardless of whether a patient
had been previously treated with a TKI, or not [26, 49,
50]. However, no OS evidence has been reported for
these subgroups. Furthermore, the number of patients in
these subgroups, particularly in the placebo arm, is
small. Importantly, there is no evidence for the efficacy
or safety of treatment with sorafenib following treatment
with lenvatinib.
The evidence presented in our review has been used
as the basis for making recommendations for practice in
England. Guidance was issued by NICE in August 2018
[64]. In drafting the guidance, the NICE Appraisal
Committee considered the uncertainties identified in our
review, alongside cost effectiveness evidence, and testi-
monies from clinical and patient experts. NICE guidance
recommends the use of lenvatinib or sorafenib for treat-
ing RR-DTC if both drugs are provided at a discounted
price [64]. However, NICE guidance also includes the re-
striction that lenvatinib or sorafenib are only available to
patients who have not previously received treatment
with a TKI or “if they have had to stop taking a TKI
within 3 months of starting it because of toxicity (specif-
ically, toxicity that cannot be managed by dose delay or
dose modification)” [64]. The reason given for this
restriction is because NICE considered that there is “not
enough clinical evidence and no cost-effectiveness
evidence to determine whether the treatments are effect-
ive when used sequentially” [64]. Restricted use of lenva-
tinib or sorafenib differs to the licensing [16–19] and
also reimbursement approval received elsewhere in the
UK [21].
Conclusions
It is not possible to reliably estimate the relative effect-
iveness of lenvatinib versus sorafenib for treating RR-
DTC, but the evidence base clearly demonstrates
improvements in PFS and ORR for these treatments
when compared with placebo, a proxy for BSC. The
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improvements in PFS and ORR are, however, accompan-
ied by an increased risk of AEs, whilst the effect on pa-
tients’ OS and HRQoL remains uncertain. Given the
slightly different safety profiles of lenvatinib and sorafe-
nib, the evidence from our review supports clinical
guideline recommendations that the choice of treatment
should consider each patient’s circumstances, including
their need for a response to treatment and
comorbidities.
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